Thierry Andre

Thierry Andre at Sorbonne University led the KEYNOTE-177 phase III trial that established pembrolizumab as first-line standard of care for MSI-H/dMMR metastatic colorectal cancer, representing a paradigm shift in CRC treatment. His research has characterized the biology of mismatch repair deficiency in CRC and defined predictive features for immunotherapy response beyond MSI status. He has been active in characterizing acquired resistance mechanisms to checkpoint inhibition in CRC. His work on immunotherapy sequencing and combination strategies in MSI-H CRC continues to shape treatment guidelines.